| Title |
A Clinical and Economic Review of Disease-Modifying Antirheumatic Drugs
|
|---|---|
| Published in |
PharmacoEconomics, September 2012
|
| DOI | 10.2165/00019053-200119070-00002 |
| Pubmed ID | |
| Authors |
Sherine E. Gabriel, Douglas Coyle, Larry W. Moreland |
| Abstract |
Rheumatoid arthritis is one of the most common chronic systemic inflammatory diseases, affecting approximately 1% of the adult population. Disease-modifying antirheumatic drugs (DMARDs) have been the mainstay of treatment for rheumatoid arthritis when combined with physical therapy and aspirin (acetylsalicylic acid) or nonsteroidal anti-inflammatory drugs. Recently, a number of new biological therapies have been introduced for the treatment of this condition and will have a major impact on the future management of this disabling disease. In this review, we summarise data on the efficacy and tolerability of the currently available DMARDs, including gold compounds, antimalarials, penicillamine, cytotoxic drugs (azathioprine and cyclophosphamide), sulfasalazine, methotrexate, leflunomide, cyclosporin, anti-tumour necrosis factor agents, combination therapy and apheresis. A literature review and quality assessment of economic evaluations of DMARDs is presented, illustrating that there has been a paucity of economic evaluations on these agents and showing the variable quality of those studies that are available. The manuscript also addresses the pharmacoeconomic implications of the new agents for rheumatoid arthritis; the need for formal long term economic evaluations in order to determine the cost effectiveness of these costly, but highly effective, new treatments is emphasised. |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 4% |
| Unknown | 22 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 5 | 22% |
| Student > Ph. D. Student | 3 | 13% |
| Other | 2 | 9% |
| Student > Master | 2 | 9% |
| Student > Doctoral Student | 2 | 9% |
| Other | 4 | 17% |
| Unknown | 5 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 8 | 35% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 17% |
| Business, Management and Accounting | 2 | 9% |
| Psychology | 1 | 4% |
| Economics, Econometrics and Finance | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 7 | 30% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 January 2006.
All research outputs
#8,534,528
of 25,373,627 outputs
Outputs from PharmacoEconomics
#996
of 1,991 outputs
Outputs of similar age
#64,933
of 189,935 outputs
Outputs of similar age from PharmacoEconomics
#228
of 550 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,991 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 189,935 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 44th percentile – i.e., 44% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 550 others from the same source and published within six weeks on either side of this one. This one is in the 6th percentile – i.e., 6% of its contemporaries scored the same or lower than it.